Xortx Therapeutics - Common Shares (XRTX) closed at $1.03 on October 29, 2026, down 1.9% from the previous close, on volume of 11,557 shares (30-day average 1,383,680).
Data as of October 29, 2026.
Market Chameleon (Fri, 9-Oct 5:53 AM ET)
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
Globe Newswire (Thu, 8-Oct 4:00 PM ET)
Globe Newswire (Fri, 18-Sep 8:05 AM ET)
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO
Globe Newswire (Thu, 10-Sep 4:05 PM ET)
XORTX Re-Engages Investor Relations Program
Globe Newswire (Tue, 8-Sep 6:15 PM ET)
XORTX Announces Termination and Postponement of Investor Relations Program
Globe Newswire (Fri, 28-Aug 7:00 AM ET)
XORTX Announces Director Resignation
Globe Newswire (Fri, 31-Jul 5:00 PM ET)
Nasdaq Compliance Secured: XRTX Cures Minimum Bid Deficiency with Timely Reverse Split
Market Chameleon (Tue, 21-Apr 5:53 AM ET)
XORTX Acquires Renal Anti-Fibrotic Program Targeting Unmet Needs in Kidney Disease
Market Chameleon (Fri, 17-Oct 5:53 AM ET)
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Xortx Therapeutics - Common Shares trades on the NASDAQ stock market under the symbol XRTX.
As of October 30, 2026, XRTX stock price declined to $1.02 with 10,815 million shares trading.
XRTX has a beta of 0.09, meaning it tends to be less sensitive to market movements. XRTX has a correlation of 0.00 to the broad based SPY ETF.
XRTX has a market cap of $1.85 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, XRTX traded as high as $35.00 and as low as $.83.
XRTX has underperformed the market in the last year with a price return of -68.6% while the SPY ETF gained +11.3%. XRTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -50.5% and -28.2%, respectively, while the SPY returned +4.1% and -1.9%, respectively.
XRTX support price is $.92 and resistance is $1.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XRTX shares will trade within this expected range on the day.
